PDS Biotechnology

Suspicious activity violating TipRanks' Terms of Use detected, including excessive page views or use of bots. Account typically reactivates within 24 hours; contact support if still disabled.

Alliance Global Partners lowers PDS Biotechnology's price target to $4.50 from $7, maintaining a Buy rating. The firm anticipates the VERSATILE-003 Phase 3 trial, combining PDS0101 and Keytruda, to start in Q1 2025. Merck's Keytruda success in KEYNOTE-689 is unlikely to impact the Versamune double combination due to limited HIV16+ patient enrollment.

PDS Biotechnology Corp reported a Q3 2024 net loss of $10.7 million, or $0.29 per share, missing analyst estimates. The company's revenue was $0.00 million, in line with expectations. PDSB is advancing its VERSATILE-003 Phase 3 trial for HPV16-positive head and neck squamous cell cancer, aiming to reduce costs and expedite data readouts. Financial challenges include increased R&D expenses to $6.8 million and a cash cushion of $49.8 million as of September 30, 2024.

PDS Biotechnology (PDSB) to report Q4 2024 EPS of $-0.28 on 2024-11-14, with investors anticipating positive guidance. Last quarter, EPS beat estimates by $0.11, causing a 0.98% drop in share price. Shares currently trading at $2.96, down 56.38% over the last 52 weeks.

PDS Biotechnology (NASDAQ:PDSB) to release earnings on Nov 14th, expected EPS of ($0.29). Last quarter, PDSB reported ($0.23) EPS, beating estimates by $0.08. Stock down 8.9%, trading at $2.96 with a 52-week range of $2.53-$6.85. Analysts have mixed ratings, with an average 'Moderate Buy' and target price of $14.25. PDS Biotechnology is a clinical-stage biopharmaceutical company focusing on cancer immunotherapies.

PDS Biotechnology (NASDAQ:PDSB) was downgraded to a 'sell' rating by StockNews.com. HC Wainwright maintained a 'buy' rating with a $21.00 price target, while Alliance Global Partners upgraded to a 'strong-buy'. The company has a consensus 'Moderate Buy' rating and an average target price of $14.25. PDSB shares opened at $3.29 on Friday, with a market cap of $121.14 million. Hedge funds, including Vanguard Group Inc. and Blair William & Co. IL, increased their holdings in PDS Biotechnology.

PDS Biotechnology (NASDAQ:PDSB) was downgraded from 'hold' to 'sell' by StockNews.com. Other brokerages have varied ratings, resulting in a consensus 'Moderate Buy' rating. The stock opened at $3.29, with a market cap of $121.14 million. Institutional investors have shown mixed activity, with Vanguard Group and Blair William & Co. IL increasing their stakes.

PDS Biotechnology schedules Q3 2024 financial results conference call for Nov 14, 2024, at 8:30 AM ET, discussing financial results and clinical program updates.

PDS Biotechnology (NASDAQ:PDSB) upgraded from 'sell' to 'hold' by StockNews.com. HC Wainwright maintains 'buy' rating with $21.00 target, while Alliance Global Partners raised to 'strong-buy'. Institutional investors like Vanguard Group and Inspirion Wealth Advisors increased holdings. PDS Biotechnology develops cancer immunotherapies, with PDS0101 in Phase II trials for head and neck cancer.

StockNews.com upgraded PDS Biotechnology from 'sell' to 'hold'. Other brokerages also issued positive reports, resulting in an average 'Buy' rating and $14.25 target price. Shares traded up 0.3% to $3.20 on Friday.